Haemophilus b Conjugate and Hepatitis B Vaccine

Name: Haemophilus b Conjugate and Hepatitis B Vaccine

  • Hepatitis A and B Vaccinations
  • Hepatitis B (HBV, Hep B)
  • Meningitis
  • Sexually Transmitted Diseases in Women (STD)
  • Vaccination and Immunization Safety Information

Dosage Forms

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Injection, suspension [preservative free]:

Comvax®: Haemophilus b capsular polysaccharide 7.5 mcg (bound to Neisseria meningitidis OMPC 125 mcg) and hepatitis B surface antigen 5 mcg per 0.5 mL (0.5 mL [DSC]) [contains aluminum; contains natural rubber/natural latex in packaging]

Contraindications

Hypersensitivity to Haemophilus b vaccine, hepatitis B vaccine, yeast, or to any component of the formulation

Dosing Pediatric

Immunization: Infants: IM: 0.5 mL/dose; one dose at 2, 4, and 12-15 months of age (total of 3 doses). Note: If the recommended schedule cannot be followed, the interval between the first two doses should be at least 6 weeks and the interval between the second and third dose should be as close as possible to 8-11 months. Minimum age for first dose is 6 weeks.

Modified Schedule: Children who receive one dose of hepatitis B vaccine at or shortly after birth may receive Comvax® on a schedule of 2, 4, and 12-15 months of age

Dosing Hepatic Impairment

There are no dosage adjustments provided in the manufacturer’s labeling.

Monitoring Parameters

Monitor for syncope for 15 minutes following administration (NCIRD/ACIP 2011). If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.

Share
(web3)